Cargando…
Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents
BACKGROUND: Mantle cell lymphoma (MCL) is an aggressive type of B-cell non-Hodgkin lymphoma associated with poor prognosis. Implementation of high-dose cytarabine (araC) into induction therapy became standard-of-care for all newly diagnosed younger MCL patients. However, many patients relapse even a...
Autores principales: | Klanova, Magdalena, Lorkova, Lucie, Vit, Ondrej, Maswabi, Bokang, Molinsky, Jan, Pospisilova, Jana, Vockova, Petra, Mavis, Cory, Lateckova, Lucie, Kulvait, Vojtech, Vejmelkova, Dana, Jaksa, Radek, Hernandez, Francisco, Trneny, Marek, Vokurka, Martin, Petrak, Jiri, Klener, Pavel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4094598/ https://www.ncbi.nlm.nih.gov/pubmed/24972933 http://dx.doi.org/10.1186/1476-4598-13-159 |
Ejemplares similares
-
Detailed Functional and Proteomic Characterization of Fludarabine Resistance in Mantle Cell Lymphoma Cells
por: Lorkova, Lucie, et al.
Publicado: (2015) -
Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells
por: Otáhal, Pavel, et al.
Publicado: (2015) -
Complex genetic and histopathological study of 15 patient-derived xenografts of aggressive lymphomas
por: Jakša, Radek, et al.
Publicado: (2022) -
Drug Resistance in Non-Hodgkin Lymphomas
por: Klener, Pavel, et al.
Publicado: (2020) -
Differential expression, localization and activity of MARCKS between mantle cell lymphoma and chronic lymphocytic leukemia
por: Vargova, J, et al.
Publicado: (2016)